BioXcel Therapeutics Company Top Insiders

BTAI Stock  USD 2.33  0.03  1.27%   
BioXcel Therapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding BioXcel Therapeutics suggests that almost all insiders are panicking. BioXcel Therapeutics employs about 74 people. The company is managed by 16 executives with a total tenure of roughly 24 years, averaging almost 1.0 years of service per executive, having 4.63 employees per reported executive.
Vimal Mehta  CEO
President CEO, Secretary, Director

Insider Sentiment 0

 Mostly Selling

 
Selling
 
Buying

Latest Trades

2024-12-16Vincent O'neillDisposed 10 @ 5.6View
2024-10-03Richard I SteinhartDisposed 448 @ 8.8View
2024-09-16Vimal MehtaDisposed 123 @ 11.04View
2024-06-17Vimal MehtaDisposed 133 @ 20.48View
2024-06-04Vimal MehtaDisposed 7875 @ 26.08View
2024-04-04Vincent O'neillDisposed 10 @ 41.92View
Monitoring BioXcel Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioXcel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.

BioXcel Therapeutics' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with BioXcel Therapeutics' future performance. Based on our forecasts, it is anticipated that BioXcel will maintain a workforce of under 70 employees by April 2025.
 
Covid

BioXcel Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.6212) % which means that it has lost $0.6212 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (17.6694) %, meaning that it created substantial loss on money invested by shareholders. BioXcel Therapeutics' management efficiency ratios could be used to measure how well BioXcel Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The BioXcel Therapeutics' current Return On Equity is estimated to increase to 3.83, while Return On Tangible Assets are projected to decrease to (2.30). As of now, BioXcel Therapeutics' Non Current Assets Total are increasing as compared to previous years. The BioXcel Therapeutics' current Debt To Assets is estimated to increase to 1.30, while Non Currrent Assets Other are projected to decrease to under 95 K.
The current Common Stock Shares Outstanding is estimated to decrease to about 21.5 M. The BioXcel Therapeutics' current Net Loss is estimated to increase to about (141.7 M)

BioXcel Therapeutics Workforce Comparison

BioXcel Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 4,083. BioXcel Therapeutics claims roughly 74.0 in number of employees contributing just under 2% to equities under Health Care industry.

BioXcel Therapeutics Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific BioXcel Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on BioXcel Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, BioXcel Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2025-03-01
1.4
14
10
 1,273,356 
 29,356 
2024-12-01
0.6
12
20
 713,129 
 73,216 
2024-09-01
0.8824
15
17
 116,882 
 14,023 
2024-06-01
0.5333
16
30
 96,379 
 1,468,470 
2024-03-01
1.2
12
10
 33,694 
 27,694 
2023-12-01
1.0
5
5
 4,693 
 4,693 
2023-09-01
1.0
5
5
 4,694 
 4,694 
2023-06-01
0.5556
15
27
 204,693 
 299,978 
2023-03-01
0.8148
22
27
 604,486 
 369,742 
2022-12-01
0.3333
3
9
 90,000 
 205,344 
2022-06-01
9.0
9
1
 127,000 
 17,000 
2021-06-01
0.8
4
5
 68,500 
 1,907,500 
2021-03-01
0.3793
11
29
 406,917 
 167,500 
2020-12-01
0.5
2
4
 50,000 
 25,000 
2020-09-01
0.6
3
5
 320,000 
 800,000 
2020-06-01
11.0
11
1
 670,000 
 20,000 
2020-03-01
0.6667
2
3
 95,000 
 680,000 
2019-06-01
2.5
5
2
 222,800 
 5,700 
2018-09-01
1.0
1
1
 90,000 
 90,000 
2018-03-01
0.6
6
10
 176,195 
 1,476,510 

BioXcel Therapeutics Notable Stakeholders

A BioXcel Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as BioXcel Therapeutics often face trade-offs trying to please all of them. BioXcel Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting BioXcel Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Vimal MehtaPresident CEO, Secretary, DirectorProfile
Richard MBASenior CFOProfile
Krishnan NandabalanChief DirectorProfile
Javier JDChief VPProfile
BSc MDChief VPProfile
Frank YoccaChief Scientific OfficerProfile
Mary ColemanVP RelationsProfile
Javier RodriguezChief VPProfile
Cedric BurgVP ManagementProfile
Robert ScalaVice PlanningProfile
Chetan LathiaClinical MedicineProfile
Robert MDChief NeuroscienceProfile
Matthew WileySenior OfficerProfile
Iris FrancesconiMarket MarketingProfile
MD BScVP OfficerProfile
Friso PostmaSenior intelligenceProfile

About BioXcel Therapeutics Management Performance

The success or failure of an entity such as BioXcel Therapeutics often depends on how effective the management is. BioXcel Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of BioXcel management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the BioXcel management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(2.19)(2.30)
Return On Capital Employed(4.25)(4.04)
Return On Assets(2.19)(2.30)
Return On Equity 3.64  3.83 

BioXcel Therapeutics Workforce Analysis

Traditionally, organizations such as BioXcel Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare BioXcel Therapeutics within its industry.

BioXcel Therapeutics Manpower Efficiency

Return on BioXcel Therapeutics Manpower

Revenue Per Employee18.6K
Revenue Per Executive86.2K
Net Loss Per Employee2.4M
Net Loss Per Executive11.2M
Working Capital Per Employee606.4K
Working Capital Per Executive2.8M

Complementary Tools for BioXcel Stock analysis

When running BioXcel Therapeutics' price analysis, check to measure BioXcel Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioXcel Therapeutics is operating at the current time. Most of BioXcel Therapeutics' value examination focuses on studying past and present price action to predict the probability of BioXcel Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioXcel Therapeutics' price. Additionally, you may evaluate how the addition of BioXcel Therapeutics to your portfolios can decrease your overall portfolio volatility.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Money Managers
Screen money managers from public funds and ETFs managed around the world
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Stocks Directory
Find actively traded stocks across global markets
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets